On October 16, 2026, the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) initiated a formal safety review of Deanxit, a fixed-dose combination of flupentixol (an antipsychotic) and melitracen (a tricyclic antidepressant), following reports of serious neurological and psychiatric adverse events. The review, formally opened during the PRAC meeting of October 26–29, 2026, targets the product’s national marketing authorizations across EU member states, Deanxit holds no centrally authorized EMA approval and holds no centrally authorized EMA approval and was not authorized through the centralized procedure’s benefit-risk assessment process. That structural fact is precisely what makes this review consequential.
The PRAC’s signal detection work operates under GVP Module IX (Signal Management, Rev 1), which establishes the EU’s sequential but flexible process for evaluating post-authorization safety signals: signal detection, validation, confirmation, and prioritization before a formal assessment is triggered. The fact that PRAC advanced Deanxit to a formal review, bypassing extended validation, indicates the incoming adverse event data crossed the committee’s threshold for urgent prioritization. Under GVP Module IX, formal assessment is triggered when signal evaluation indicates a potential change to the product’s risk-benefit balance may be warranted.
What the Deanxit Review Actually Covers
Deanxit’s safety profile carries a documented cardiovascular liability that may be driving at least part of the signal. Flupentixol is a recognized cause of QT prolongation, with associated risk of Torsades de Pointes and sudden cardiac death, a risk category that PRAC has historically treated as requiring explicit labeling controls and, in some cases, restricted indication scope. Combined with melitracen’s tricyclic pharmacology, which carries its own cardiac conduction effects at therapeutic doses, the fixed-dose pairing creates an additive exposure profile that is difficult to manage through standard prescriber guidance alone.
The EMA’s Guideline on Clinical Development of Fixed Combination Medicinal Products (Revision 2) requires that each component of a fixed-dose combination contribute independently to the product’s clinical effect, and that the combination’s benefit-risk balance be demonstrably superior to either component used alone. For Deanxit, that combination rationale was established through national authorization processes that predate the current guideline’s evidentiary standards. The PRAC review, in effect, subjects that older benefit-risk justification to contemporary pharmacovigilance scrutiny, a form of post-market re-examination that the centralized procedure would have required prospectively.
Sponsors designing fixed-dose CNS programs should read that last point carefully. A product that clears national authorization under legacy standards can be pulled back to a full benefit-risk reassessment the moment post-authorization data generates a priority signal under GVP Module IX. The authorization pathway chosen at launch does not insulate a product from post-market PRAC action.
Operational Implications for CNS Sponsors and Trial Designers
For sponsors with active IND or CTA filings in depression and anxiety indications, the Deanxit review introduces three immediate protocol-level considerations. First, any trial that permits Deanxit as a concomitant medication, particularly in EU member states where it holds national authorization, now carries an elevated pharmacovigilance burden. Under ICH E6(R2), investigators are required to report all serious adverse events regardless of suspected causality, and an ongoing PRAC review of a co-administered product will increase regulatory reviewers’ sensitivity to any neurological or psychiatric SAEs in those arms.
Second, sponsors developing their own fixed-dose CNS combinations face a changed comparator environment. If PRAC restricts Deanxit‘s indications or mandates contraindications in specific patient populations, among the possible outcomes of a GVP Module IX formal assessment, the standard of care landscape in EU member states shifts, potentially affecting trial eligibility criteria, background therapy rules, and the composition of active-comparator arms. Sponsors should model both restriction scenarios now rather than wait for PRAC’s assessment report, the timing of which has not been publicly specified by EMA.
Third, IRBs and ethics committees in EU member states reviewing protocols that include flupentixol-containing products, either as investigational agents or permitted concomitant medications, will likely request additional risk justification in light of the active PRAC review. Protocol teams should prepare a standing safety narrative for Deanxit that addresses the QT prolongation liability and the ongoing regulatory assessment, and have it available for submission to competent authorities without delay.
The Broader Pattern: Post-Market Scrutiny of Combination CNS Products
The Deanxit review does not stand alone. It sits inside ongoing PRAC scrutiny of combination psychiatric products, particularly where the fixed-dose rationale relies on historical clinical data that would not meet current evidentiary standards under the Fixed Combination Guideline (Revision 2). The EMA’s 2013 guideline on clinical investigation of medicinal products for depression, referenced by RAPS in coverage of EMA’s depression-focused regulatory framework, already signaled that add-on and augmentation therapies would face heightened requirements, Deanxit’s current review represents the post-market enforcement of that standard for products that pre-dated it.
Investors tracking CNS portfolios with EU exposure should note that the national-authorization structure of Deanxit’s market presence means PRAC’s outcome will likely be communicated to member state competent authorities via a referral recommendation rather than a centralized label change. The practical effect can be equivalent, coordinated labeling restrictions or suspension across member states, but the procedural pathway is less visible to external observers who monitor only the EMA’s centralized authorization database.
Sponsors with Phase 2 or Phase 3 CNS programs in EU jurisdictions should, before the end of Q4 2026, audit their protocols for Deanxit concomitant-medication exposure, update their pharmacovigilance plans to reference the active PRAC review, and prepare IRB-ready risk narratives addressing flupentixol’s QT liability. The next relevant regulatory signal to monitor is PRAC’s preliminary assessment report on the Deanxit referral, the timing of which EMA has not publicly specified, at which point restriction language, if any, will begin to appear in updated national SmPCs across EU markets.
References
- EMA, “Meeting Highlights: PRAC 26–29 October 2026”
- EMA, Flupentixol/Melitracen-Containing Medicinal Products Referral Page
- EMA, “Guideline on Good Pharmacovigilance Practices (GVP) Module IX: Signal Management (Rev 1)”
- EMA, “Guideline on Clinical Development of Fixed Combination Medicinal Products (Revision 2)”
- EMA, “ICH Guideline for Good Clinical Practice E6(R2), Step 5”
- Davis Drug Guide, Flupentixol: QT Prolongation and Cardiovascular Risk Profile
- RAPS, “New EMA Guideline on Depression Focused on Special Populations”
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
